Abstract
In 2011, new tools to evaluate life expectancy are available. Controversy about PSA-based screening for prostate cancer is still going on, with new data from the US Preventive services task force. A brief behavioral treatment for insomnia can be efficient and durable. Gliptines are be useful to avoid treatment-induced hypoglycemia in diabetic patients. New Alzheimer diagnostic criteria, including biomarkers, have been published.
MeSH terms
-
Aging*
-
Alzheimer Disease* / diagnosis
-
Behavior Therapy
-
Biomarkers, Tumor / blood
-
Diabetes Mellitus, Type 2* / drug therapy
-
Dipeptidyl-Peptidase IV Inhibitors / administration & dosage
-
Dipeptidyl-Peptidase IV Inhibitors / adverse effects
-
Early Detection of Cancer
-
Geriatrics / trends
-
Humans
-
Hypoglycemic Agents / administration & dosage
-
Hypoglycemic Agents / adverse effects
-
Life Expectancy*
-
Male
-
Mass Screening
-
Prostate-Specific Antigen / blood
-
Prostatic Neoplasms* / blood
-
Prostatic Neoplasms* / diagnosis
-
Prostatic Neoplasms* / prevention & control
-
Psychotherapy, Brief
-
Randomized Controlled Trials as Topic
-
Sleep Initiation and Maintenance Disorders* / therapy
Substances
-
Biomarkers, Tumor
-
Dipeptidyl-Peptidase IV Inhibitors
-
Hypoglycemic Agents
-
Prostate-Specific Antigen